The company's revenues were driven by its centralized and point-of-care solutions as well as its molecular diagnostics business, both rising in the single digits.
The company said it processed around 200,000 tests in the third quarter, representing approximately 20 percent growth over the year-ago quarter.
The new schizophrenia risk genes, among them two encoding glutamate receptor subunits, appear to have some overlap with genes involved in autism spectrum disorder.
Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.
The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.
The proceeds from the sale will go toward the planned acquisition of Curetis and to support the ongoing submission of its technology to US regulators.
The bank believes investors are too focused on the potential of PacBio's merger with Illumina falling through rather than recent developments regarding its technology.
Users can apply both companies' tools to view genomic evidence linked to disease mutations, reducing the time needed to examine a variant's pathogenicity.
PetaGene is expanding further into South Asia and other regions by naming Dubai-based Alliance Global as its exclusive partner in several countries.
The buccal epithelial cell-based epigenetic clock corresponded with age in those under 20, but skewed slightly higher in a small subset of children with autism spectrum disorder.
The project will provide approved researchers with access to samples and deidentified data collected from volunteer patients with Duchenne muscular dystrophy.
With the certification, the Silicon Valley-based company aims to roll out its AvaGen test for keratoconus and corneal dystrophies beginning this quarter.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
Last week, GenomeWeb's readers were most interested in announcement from Qiagen that it has partnered with Illumina to develop NGS-based IVD kits.
The companies will develop an assay to guide treatment with a type of radiopharmaceutical therapy in patients with these rare tumors.
The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.
Investigators at the Foundation for Research and Technology - Hellas, a Greek research institute, are coordinating the effort.
Thousands of parent-child exomes helped researchers identify apparently causative mobile element insertions in a handful of children with developmental disorders.
The test, TruGraf, assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.
The companies are collaborating to return actionable genetic information to all participants of the Project Baseline Health Study.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.